We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Roche Diagnostics

Develops, manufactures, and markets a wide range of in vitro diagnostic systems, instruments, reagents, and tests read more Featured Products: More products

Download Mobile App




Mouth Swab Molecular Test for Tuberculosis Validated

By LabMedica International staff writers
Posted on 22 Jan 2020
Clinical investigators are testing an approach being developed to diagnose tuberculosis using mouth swabs, which could become an alternate approach to sample collection methods currently used to do tuberculosis (TB) testing.

Partly because of the convenience of the collection method, the technique is helping increase access to testing and finding people with TB that have been undetected by traditional testing methods. More...
For individuals with latent TB infection, the host maintains a dynamic relationship with Mycobacterium tuberculosis through the regulation of available nutrients as well as the innate and acquired immune systems.

Scientists at the University of Pretoria (Pretoria, South Africa) and their colleagues collected and tested samples from people during house visits in an urban setting in South Africa with a high prevalence of TB and human immunodeficiency viruses (HIV). The team used flocked swabs to collect oral salivary specimens from 73 adults. Each person had a cough and one or more risk factors for TB, including previous TB, or was asymptomatic but residing with someone diagnosed with TB.

The investigators combined the swab samples that they had collected with PrimeStore Molecular Transport Medium (MTM, Longhorn Vaccines and Diagnostics, San Antonio, TX, USA) to enable microbial inactivation, DNA stabilization, and transportation of the specimens at ambient temperature to a nearby laboratory. The group detected M. tuberculosis DNA in 24, or 32.9%, of the 73 samples using Longhorn's polymerase chain reaction (PCR) diagnostic assay running on a Roche LightCycler platform (Roche Diagnostics, Basel, Switzerland).

P. Bernard Fourie, PhD, a professor of medical microbiology and TB specialist, said, “The approach holds promise as an easy to perform, safe, and patient-friendly procedure for triaging people who are presumed to have TB at the household level, and it provides a basis for targeted patient follow-up.”

Related Links:
University of Pretoria
Longhorn Vaccines and Diagnostics
Roche Diagnostics



New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gel Cards
DG Gel Cards
Laboratory Software
ArtelWare
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: The initiative aims to speed next-generation diagnostic development during early pathogen emergence (photo courtesy of 123RF)

Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss

Cepheid (Sunnyvale, CA, USA) has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators in a federal initiative to speed rapid diagnostic technologies... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.